You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

62 Results
Regimen
Cancer Type:
Genitourinary, 
Prostate
Intent: Curative, Palliative
Funding:
ODB - General Benefit
    relugolix
Updated
May 2025
Regimen
Cancer Type:
Gastrointestinal, 
Colorectal
Intent: Palliative
Aug 2023
Regimen
Cancer Type:
Gastrointestinal, 
Esophagus, 
Gastric / Stomach
Intent: Palliative
Mar 2023
Guidelines and Advice
Regimen
Cancer Type:
Gastrointestinal, 
Gastrointestinal Stromal Tumours
Intent: Palliative
Funding:
Exceptional Access Program
    ripretinib - For adult patients with advanced gastrointestinal stromal tumours (GIST) who have progression on or intolerance to imatinib, sunitinib and regorafenib
Aug 2023
Regimen
Cancer Type:
Hematologic, 
Leukemia - Acute Lymphoblastic (ALL), 
Lymphoma - Non-Hodgkin's High Grade, 
Lymphoma - Non-Hodgkin's Intermediate Grade
Intent: Curative
Aug 2020
Drug
Other Name(s): Rituxan® , Truxima™ , Riximyo™ , Ruxience™ , Riabni™
Apr 2025
Drug
Other Name(s): Rituxan® SC
Apr 2025
Drug
Other Name(s): Istodax®
Mar 2023
Drug
Other Name(s): Jakavi®
Mar 2025
Drug
Other Name(s): Kisqali™
Jan 2022
Drug
Other Name(s): Cyramza®
Mar 2023

Pages